Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy

Neurology

Volumn 76, Issue 13, 2011, Pages 1126-1134

  Gong, Xing ^a   Schwartz, Philip H ^b   Linskey, Mark E ^a,c   Bota, Daniela A ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Children's Hospital   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; BREAST CANCER RESISTANCE PROTEIN; CASPASE 3; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; PROTEASOME; TEMOZOLOMIDE;

ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL ACTIVITY; CELL COUNT; CELL CULTURE; CELL DEATH; CELL EXPANSION; CELL ISOLATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GLIOMA; GLIOMA CELL; GLIOMA STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MULTIDRUG RESISTANCE; NEURAL STEM CELL; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR GROWTH;

EID: 79954484430     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318212a89f     Document Type: Article

References (40)

1. 2010 CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. In: Central Brain Tumor Registry of the United States. Available at: http://www.cbtrus.org/reports/ reports.html. Accessed March 2010.
2. Schmidinger M, Linzmayer L, Becherer A, et al. Psychometric and quality-of-life assessment in long-term glioblastoma survivors. J Neurooncol 2003;63:55-61. (Pubitemid 36681643)
3. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 1990;28:818-822.
4. Corn BW, Wang M, Fox S, et al. Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. J Neurooncol 2009;95:247-257.
5. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485-493. (Pubitemid 34072533)
6. Armand JP, Macquet JP, LeRoy AF. Cerebrospinal fluidplatinum kinetics of cisplatin in man. Cancer Treat Rep 1983;67:1035-1037. (Pubitemid 14208709)
7. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10:3728-3736. (Pubitemid 38697606)
8. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
9. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43. (Pubitemid 32530848)
10. Diestra JE, Scheffer GL, Català I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/ MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002;198:213-219. (Pubitemid 35243879)
11. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-887. (Pubitemid 41417939)
12. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-142. (Pubitemid 41095125)
13. Gregory JK, Maria W-W, Mitchell M, et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2009;74:433-439.
14. Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS- 341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2004;24:344-354.
15. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006;12:2264-2271.
16. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-7848. (Pubitemid 44299144)
17. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-5828. (Pubitemid 37187480)
18. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
19. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
20. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133- cancer stem cells in glioblastoma. Molecular Cancer 2006;5:67.
21. Reynolds B, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992;255:1707-1710.
22. Saxe MD, Battaglia F, Wang J-W, et al. Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. Proc Natl Acad Sci 2006;103:17501-17506. (Pubitemid 44788998)
23. Trouche SP, Bontempi B, Roullet P, Rampon C. Recruitment of adult-generated neurons into functional hippocampal networks contributes to updating and strengthening of spatial memory. Proc Natl Acad Sci 2009;106:5919-5924.
24. Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat Med 2002;8:955-962. (Pubitemid 35033699)
25. Seigers R, Schagen SB, Beerling W, et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008;186:168-175. (Pubitemid 350122748)
26. Schwartz PH, Bryant PJ, Fuja TJ, Su H, O'Dowd DK, Klassen H. Isolation and characterization of neural progenitor cells from post-mortem human cortex. J Neurosci Res 2003;74:838-851. (Pubitemid 37490416)
27. Pistollato F, Chen H-L, Rood BR, et al. Hypoxia and HIF1alpha repress the differentiative effects of BMPs in high-grade glioma. Stem Cells 2009;27:7-17.
28. Crompton T, Peitsch MC, MacDonald HR, Tschopp J. Propidium iodide staining correlates with the extent of DNA degradation in isolated nuclei. Biochem Biophys Res Commun 1992;183:532-537.
29. Ri M, Iida S, Nakashima T, et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010;24:1506-1512.
30. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit-5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008;112:2489-2499.
31. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996. (Pubitemid 40349501)
32. Samano A, Ohshima-Hosoyama S, Whitney T, et al. Functional evaluation of therapeutic response for a mouse model of medulloblastoma. Transgenic Res 2010;19:829-840.
33. Phuphanich S, Supko J, Carson K, et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neuro-Oncol Epub 2010 Mar 8.
34. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60: 1383-1387. (Pubitemid 30152011)
35. Burrows RC, Wancio D, Levitt P, Lillien L. Response diversity and the timing of progenitor cell maturation are regulated by developmental changes in EGFR expression in the cortex. Neuron 1997;19:251-267. (Pubitemid 27374226)
36. Monje M. Cranial radiation therapy and damage to hippocampal neurogenesis. Dev Disabil Res Rev 2008;14: 238-242.
37. Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004;62:548-555. (Pubitemid 38252794)
38. Nomura Y, Yasumoto S, Yanai F, et al. Survival and late effects on development of patients with infantile brain tumor. Pediatr Int 2009;51:337-341.
39. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 2009;10:459-466.
40. Van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J Clin Oncol 2009;27:1268-1274.